A 6-WEEK INTERNATIONAL, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE FEASIBILITY OF SWITCHING FROM IMMEDIATE-REALESE QUETIAPINE FUMARATE SEROQUEL TM TO SUSTAINED-REALESE QUETIAPINE FUMARATE 400 to 800 mg/day IN OUTPATIENTS WITH SCHIZOPHRENIA
- Conditions
- SCHIZOPHRENIAMedDRA version: 6.1Level: HLTClassification code 10039631
- Registration Number
- EUCTR2004-000912-13-IT
- Lead Sponsor
- ASTRAZENECA AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method